US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

8.40

-0.5400-6.04%

Post-market: 8.500.1000+1.19%19:16 EDT

Volume:1.39M

Turnover:12.03M

Market Cap:262.84M

PE:-2.95

High:9.25

Open:8.90

Low:8.40

Close:8.94

52wk High:50.40

52wk Low:8.40

Shares:31.29M

Float Shares:15.69M

Volume Ratio:0.67

T/O Rate:8.88%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8500

EPS(LYR):-2.8503

ROE:-33.63%

ROA:-21.86%

PB:0.92

PE(LYR):-2.95

Loading ...

Overview Company News Filings

Bicycle Therapeutics price target lowered to $36 from $44 at Oppenheimer

Xortx Therapeutics announces three new director nominees

RBC Cuts Price Target on Bicycle Therapeutics to $7 From $11, Keeps Sector Perform, Speculative Risk

MT Newswires Live

Ovid Therapeutics Shares Rise After Swinging to 4Q Profit, Expanding Treatment

Ovid Therapeutics sees cash runway into late 2028

Ovid Therapeutics announces OV239 data, indication expansion

Bicycle Therapeutics Is Maintained at Buy by Needham

Ovid Therapeutics Q4 EPS $0.06 Beats $(0.11) Estimate, Sales $718.000K Beat $13.333K Estimate

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Press Release: Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Arcturus Therapeutics initiated with a Buy at B. Riley

Chordia Therapeutics Doses First Patient in Rogocekib Expansion Cohort

Assertio Therapeutics Banks on Robodon After Volatile Q4

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Press Release: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

Akari Therapeutics announces ADS ratio change

Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)

AN2 Therapeutics Q4 EPS $(0.29) Misses $(0.24) Estimate

Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":8.4,"timestamp":1774641600000,"preClose":8.94,"halted":0,"volume":1393631,"hourTrading":{"tag":"盘后","latestPrice":8.5,"preClose":8.4,"latestTime":"19:16 EDT","volume":25181,"amount":211529.72,"timestamp":1774653413550,"change":0.1,"changeRate":0.011905,"amplitude":0.011905},"delay":0,"changeRate":-0.060402684563758295,"floatShares":15692500,"shares":31289969,"eps":-2.85,"marketStatus":"Market Closed","change":-0.54,"latestTime":"03-27 16:00:00 EDT","open":8.9,"high":9.25,"low":8.395,"amount":12026989.540177,"amplitude":0.095638,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.85,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":8.94,"preHourTrading":{"tag":"盘前","latestPrice":8.95,"preClose":8.94,"latestTime":"09:25 EDT","volume":2891,"amount":25925.149467,"timestamp":1774617913255,"change":0.01,"changeRate":0.001119,"amplitude":0.016779},"postHourTrading":{"tag":"盘后","latestPrice":8.5,"preClose":8.4,"latestTime":"19:16 EDT","volume":25181,"amount":211529.72,"timestamp":1774653413550,"change":0.1,"changeRate":0.011905,"amplitude":0.011905},"volumeRatio":0.6705382154646017,"impliedVol":1.3191,"impliedVolPercentile":0.9877},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":15692500,"roa":"-21.86%","roe":"-33.63%","lyrEps":-2.850329,"volumeRatio":0.6705382154646017,"shares":31289969,"dividePrice":0,"high":9.25,"amplitude":0.095638,"preClose":8.94,"low":8.395,"week52Low":8.395,"pbRate":"0.92","psRate":"13.77","week52High":50.4,"institutionHeld":0,"latestPrice":8.4,"eps":-2.85,"divideRate":0,"volume":1393631,"delay":0,"ttmEps":-2.85,"open":8.9,"prevYearClose":16,"prevWeekClose":10.48,"prevMonthClose":13.49,"prevQuarterClose":16,"fiveDayClose":10.48,"twentyDayClose":13.49,"sixtyDayClose":16.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59},{"market":"US","date":"2025-07-30","symbol":"LENZ","fiscalQuarterEnding":"2025/06","expectedEps":-0.58,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753848000000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.4286,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5714,"analysts":7,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-03-27","current":-2.947368,"percent":1,"low":-26.69966,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"high":-3.413108,"avg":-12.467749,"sd":5.207963,"marketCap":280308282},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282}],"updateTime":1774753325999},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620258221","title":"Bicycle Therapeutics price target lowered to $36 from $44 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620258221","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620258221?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:45","pubTimestamp":1773834312,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Jay Olson lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $36 from $44 and keeps an Outperform rating on the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-price-target-lowered-to-36-from-44-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-price-target-lowered-to-36-from-44-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","OPY"],"gpt_icon":0},{"id":"2620258842","title":"Xortx Therapeutics announces three new director nominees","url":"https://stock-news.laohu8.com/highlight/detail?id=2620258842","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620258842?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:26","pubTimestamp":1773833201,"startTime":"0","endTime":"0","summary":"XORTX Therapeutics (XRTX) announces that, in connection with its upcoming annual and special meeting of shareholders to be held on March 24, three ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xortx-therapeutics-announces-three-new-director-nominees-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xortx-therapeutics-announces-three-new-director-nominees-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XRTX","BK4007","BK4539","LENZ"],"gpt_icon":0},{"id":"2620723710","title":"RBC Cuts Price Target on Bicycle Therapeutics to $7 From $11, Keeps Sector Perform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2620723710","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620723710?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:56","pubTimestamp":1773831381,"startTime":"0","endTime":"0","summary":"Bicycle Therapeutics (BCYC) has an average rating of overweight and mean price target of $12.78, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"gpt_icon":0},{"id":"2620232091","title":"Ovid Therapeutics Shares Rise After Swinging to 4Q Profit, Expanding Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232091","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232091?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:56","pubTimestamp":1773831360,"startTime":"0","endTime":"0","summary":"Shares of Ovid Therapeutics climbed after the company swung to a profit in the fourth quarter and said it would expand one of its therapies to explore additional use cases.The stock rose 22%, to $2.48, in premarket trading Wednesday. Through Tuesday's close, shares have more than quadrupled over the past year.The biopharmaceutical company swung to a profit of $9.66 million from a loss of $9.28 million a year earlier. Quarterly earnings of 6 cents a share topped analyst expectations for a loss of 12 cents a share, according to FactSet.Total revenues of $718,000 came in ahead of Wall Street models for about $100,000.Chief Executive Meg Alexander said the company is making progress to develop medicines for brain disorders.Ovid reported what it called favorable topline safety, tolerability and pharmacokinetics from a study of one of its therapies, OV329. The company also said it will add complementary development programs for the treatment, expanding into tuberous sclerosis complex seizure","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4007","OVID","BK4139"],"gpt_icon":0},{"id":"2620341032","title":"Ovid Therapeutics sees cash runway into late 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2620341032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620341032?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:15","pubTimestamp":1773828934,"startTime":"0","endTime":"0","summary":"Cash, cash equivalents and marketable securities as of December 31, 2025 totaled $90.4 million. Published first on TheFly – the ultimate source for...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ovid-therapeutics-sees-cash-runway-into-late-2028-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ovid-therapeutics-sees-cash-runway-into-late-2028-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ"],"gpt_icon":0},{"id":"2620179234","title":"Ovid Therapeutics announces OV239 data, indication expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2620179234","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620179234?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:10","pubTimestamp":1773828652,"startTime":"0","endTime":"0","summary":"Ovid announced new results from a 7 mg dose cohort evaluating the safety and tolerability of OV329, a next-generation GABA-AT inhibitor being devel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ovid-therapeutics-announces-ov239-data-indication-expansion-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ovid-therapeutics-announces-ov239-data-indication-expansion-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2620345962","title":"Bicycle Therapeutics Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2620345962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620345962?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:10","pubTimestamp":1773828600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCYC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 06:10 ET (10:10 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2620389234","title":"Ovid Therapeutics Q4 EPS $0.06 Beats $(0.11) Estimate, Sales $718.000K Beat $13.333K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620389234","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620389234?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:09","pubTimestamp":1773828549,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics (NASDAQ:OVID) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.11) by 152.63 percent. This is a 146.15 percent increase over losses of $(0.13) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51318664/ovid-therapeutics-q4-eps-0-06-beats-0-11-estimate-sales-718-000k-beat-13-333k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2620226234","title":"Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620226234","media":"GlobeNewswire","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620226234?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:05","pubTimestamp":1773828300,"startTime":"0","endTime":"0","summary":"The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in foc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3257984/0/en/Ovid-Therapeutics-Announces-New-OV329-Data-and-Indication-Expansion-Phase-1-Clearance-for-OV4071-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","LU1878469433.USD","LU1093756168.USD","BK4218","BK4539","LU0061475181.USD","TGA","BK4097","BK4139","IE00B19Z3581.USD","IS","BK4181","LU1093756325.SGD","BK4213","LENZ","BK4519","IE00B19Z3B42.SGD","BK4105","BK4585","BK4588","AES","IE00B7SZLL34.SGD","PK","BK4007"],"gpt_icon":0},{"id":"2620231222","title":"Press Release: Ovid Therapeutics Announces Pricing of $60 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620231222","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620231222?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:00","pubTimestamp":1773828000,"startTime":"0","endTime":"0","summary":"-- Proceeds expected to support expansion of next-generation. -- Financing led by Point72 with participation from additional investors. including Adage Capital Management, ADAR1 Capital Management, Affinity. Asset Advisors, LLC, Ally Bridge Group, Balyasny Asset Management,Coastlands Capital, Eventide Asset Management, Janus Henderson Investors. The Company intends to use the net proceeds from the PIPE financing, together with the Company's existing cash, cash equivalents and marketable securities, to provide financing to support the expansion of the development of OV329 into additional indications, including tuberous sclerosis complex and infantile spasms, as well as for general research and development expenses.The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended , and may not be reoffered or resold in the United States except pursuant to ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IS","OVID","LENZ","BK4007","BK4139","BK4097","BK4539"],"gpt_icon":0},{"id":"2620623981","title":"Arcturus Therapeutics initiated with a Buy at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2620623981","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620623981?lang=en_us&edition=fundamental","pubTime":"2026-03-18 17:05","pubTimestamp":1773824717,"startTime":"0","endTime":"0","summary":"B. Riley initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $22 price target The firm says the company “stands out” given its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-initiated-with-a-buy-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-initiated-with-a-buy-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","ARCT","BK4007"],"gpt_icon":0},{"id":"2620287935","title":"Chordia Therapeutics Doses First Patient in Rogocekib Expansion Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2620287935","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620287935?lang=en_us&edition=fundamental","pubTime":"2026-03-18 14:53","pubTimestamp":1773816824,"startTime":"0","endTime":"0","summary":"Chordia Therapeutics Inc. ( ($JP:190A) ) has issued an update. Chordia Therapeutics Inc. has begun dosing the first patient in the Initial Expansio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chordia-therapeutics-doses-first-patient-in-rogocekib-expansion-cohort?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chordia-therapeutics-doses-first-patient-in-rogocekib-expansion-cohort?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2620044234","title":"Assertio Therapeutics Banks on Robodon After Volatile Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2620044234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620044234?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:08","pubTimestamp":1773792500,"startTime":"0","endTime":"0","summary":"Assertio Therapeutics (($ASRT)) has held its Q4 earnings call. Read on for the main highlights of the call. Assertio Therapeutics’ latest earnings ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/assertio-therapeutics-banks-on-robodon-after-volatile-q4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/assertio-therapeutics-banks-on-robodon-after-volatile-q4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASRT","LENZ","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"2620401185","title":"Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401185","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620401185?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:54","pubTimestamp":1773784440,"startTime":"0","endTime":"0","summary":"ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257773/0/en/Acrivon-Therapeutics-to-Present-Pre-Clinical-AP3-Data-at-the-2026-AACR-Annual-Meeting-Revealing-Strong-Synergy-of-ACR-368-with-ADC-Topo-1-Inhibitor-Payloads-and-of-both-ACR-368-and.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","ADC","BK4139","BK4007","BK4231","BK4539","LENZ","BK4110","ACR"],"gpt_icon":0},{"id":"2620861405","title":"Press Release: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620861405","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620861405?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:01","pubTimestamp":1773781260,"startTime":"0","endTime":"0","summary":"Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer, reinforcing broad therapeutic potential. During the fourth quarter, Silexion achieved key clinical readiness milestones including completing two-species toxicology studies, written Scientific Advice from Germany's BfArM, and submission of Phase 2/3 clinical trial application to the Ministry of Health in Israel for SIL204 in locally advanced pancreatic cancer. The Company remains on track to initiate Phase 2/3 clinical trial in the first half of 2026, with Israel regulatory feedback anticipated by the end of Q1 2026. Regulatory Advancement Toward Phase 2/3 Initiation: Silexion received written Scientific Advice from Germany's Federal Institute for Drugs and Medical Devices  regarding the design of its planned Phase 2/3 clinical trial. The Company subsequently submitted its Phase 2/3 clini","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["API","LENZ","BK4503","BK4551","BK4023","BK4535","BK4007","SLXN","BK4539","BK4139"],"gpt_icon":0},{"id":"2620840113","title":"Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620840113","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620840113?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:45","pubTimestamp":1773780300,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., March  17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for peopl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257702/0/en/Xilio-Therapeutics-to-Present-New-Preclinical-Data-for-its-Masked-T-Cell-Engager-Program-Targeting-CLDN18-2-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4539","BK4117","BK4007","BK4139","BK4107","LENZ"],"gpt_icon":0},{"id":"2620403184","title":"Akari Therapeutics announces ADS ratio change","url":"https://stock-news.laohu8.com/highlight/detail?id=2620403184","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620403184?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:35","pubTimestamp":1773779719,"startTime":"0","endTime":"0","summary":"Akari Therapeutics announced that the company will change the ratio of its American depositary shares to ordinary shares from one ADS representing ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/akari-therapeutics-announces-ads-ratio-change-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/akari-therapeutics-announces-ads-ratio-change-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","LENZ","BK4007"],"gpt_icon":0},{"id":"2620950403","title":"Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620950403","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620950403?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:25","pubTimestamp":1773779144,"startTime":"0","endTime":"0","summary":"The company ended 2025 with $188.3M with expected cash runway into 2028. “Our progress in 2025 marked a major inflection point for Trevi’s growth t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/trevi-therapeutics-reports-q4-eps-6c-consensus-10c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/trevi-therapeutics-reports-q4-eps-6c-consensus-10c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2620408630","title":"AN2 Therapeutics Q4 EPS $(0.29) Misses $(0.24) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620408630","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620408630?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:07","pubTimestamp":1773778037,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.24) by 20.83 percent. This is a 16 percent decrease over losses of $(0.25) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51310551/an2-therapeutics-q4-eps-0-29-misses-0-24-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AN2 Therapeutics Q4 EPS $(0.29) Misses $(0.24) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2620682408","title":"Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620682408","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620682408?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:05","pubTimestamp":1773777900,"startTime":"0","endTime":"0","summary":"Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough. On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026. Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028. Management to host a conference call and webcast today at 4:30 p.m. ET. NEW HAVEN, Conn., March 17, 2026  -- Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis , non-IPF interstitial lung disease , and refractory chronic cough , today announced financial results for the fourth quarter and year ended December 31, 2025, and provided business updates.overall alignment on the plan for the remai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","TRVI","BK4585","LENZ","BK4588","TM","LABU","BK4604","BK4555","RCC","BK4007","BK4539","BK4099","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":14,"pageCount":11,"totalSize":262,"code":"91000000","status":"200"}]}}